Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

Fig. 2

Proportions of patients achieving target HbA1c levels at week 24 (Per-Protocol Set). A, Proportions of patients achieving HbA1c less than 7.0% or 6.5% at week 24. B, Proportions of patients achieving therapeutic glycemic response at week 24. The asterisks denote a statistically significant difference between the groups (*p < 0.05)

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840